Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Manfredi Carta"'
Autor:
Marco Bardelli, Karl Frontzek, Luca Simonelli, Simone Hornemann, Mattia Pedotti, Federica Mazzola, Manfredi Carta, Valeria Eckhardt, Rocco D'Antuono, Tommaso Virgilio, Santiago F González, Adriano Aguzzi, Luca Varani
Publikováno v:
PLoS Pathogens, Vol 14, Iss 10, p e1007335 (2018)
Antibodies to the prion protein, PrP, represent a promising therapeutic approach against prion diseases but the neurotoxicity of certain anti-PrP antibodies has caused concern. Here we describe scPOM-bi, a bispecific antibody designed to function as
Externí odkaz:
https://doaj.org/article/b333e425dac04363bafbe5d00b152b89
Autor:
Marc Emmenegger, A. D. Magalhaes, Simone Hornemann, Andra Chincisan, Karl Frontzek, E. De Cecco, Adriano Aguzzi, Manfredi Carta
The microtubule-associated protein tau is involved in several neurodegenerative diseases and is currently being investigated as a plasma biomarker for the detection and monitoring of Alzheimer’s disease and as an immunotherapeutical target in clini
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b7e549f9231bab61714ea2a07748c8a1
https://doi.org/10.1101/2021.11.24.21266833
https://doi.org/10.1101/2021.11.24.21266833
Publikováno v:
Cell Reports
Autor:
Cornelis Blauwendraat, John Hardy, Alessandro Crimi, Regina H. Reynolds, Mina Ryten, Dezirae Schneider, Sara Bandres-Ciga, Eleanna Kara, Daniel Heinzer, Alexandre Theocharides, Claudia Manzoni, Juan A. Botía, Marco Losa, Jordan D. Marks, Veronika Lysenko, Patrick A. Lewis, Merve Avar, Bradley T. Hyman, Sarah C. Hopp, Daniel Patrick Pease, Zhanyun Fan, Alessandra Carrella, Anne Wiedmer, Marc Emmenegger, Karishma D’Sa, Andra Chincisan, Andreia D. Magalhães, Lorene Mottier, Adriano Aguzzi, Manfredi Carta, Caroline Aemisegger, Sonia Garcia Ruiz
SummaryNeuropathological and experimental evidence suggests that the cell-to-cell transfer of a-synuclein has an important role in the pathogenesis of Parkinson’s disease (PD). However, the mechanism underlying this phenomenon is not fully understo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7e4071e59018abf3fcdf39a305b58151
https://doi.org/10.1101/2019.12.23.886838
https://doi.org/10.1101/2019.12.23.886838
Autor:
Karl, Frontzek, Manfredi, Carta, Marco, Losa, Mirka, Epskamp, Georg, Meisl, Alice, Anane, Jean-Philippe, Brandel, Ulrike, Camenisch, Joaquín, Castilla, Stéphane, Haïk, Tuomas, Knowles, Ewald, Lindner, Andreas, Lutterotti, Eric Vallabh, Minikel, Ignazio, Roiter, Jiri G, Safar, Raquel, Sanchez-Valle, Dana, Žáková, Simone, Hornemann, Adriano, Aguzzi, Gianluigi, Forloni
Publikováno v:
Neurology
OBJECTIVE: To determine whether naturally occurring autoantibodies against the prion protein are present in individuals with genetic prion disease mutations and controls, and if so, whether they are protective against prion disease. METHODS: In this
Autor:
Manfredi Carta, Werner Wichmann, Marco Losa, Karl Frontzek, Niklaus Krayenbühl, Elisabeth J. Rushing
Publikováno v:
Brain Pathol
Autor:
Federica Mazzola, Valeria Eckhardt, Rocco D'Antuono, Manfredi Carta, Marco Bardelli, Simone Hornemann, Mattia Pedotti, Luca Simonelli, Adriano Aguzzi, Tommaso Virgilio, Luca Varani, Karl Frontzek, Santiago F. Gonzalez
Publikováno v:
PLoS Pathogens
PLoS Pathogens, Vol 14, Iss 10, p e1007335 (2018)
PLoS Pathogens, Vol 14, Iss 10, p e1007335 (2018)
Antibodies to the prion protein, PrP, represent a promising therapeutic approach against prion diseases but the neurotoxicity of certain anti-PrP antibodies has caused concern. Here we describe scPOM-bi, a bispecific antibody designed to function as
Autor:
Stéphane Haïk, Ignazio Roiter, Andreas Lutterotti, Jean-Philippe Brandel, Tuomas P. J. Knowles, Simone Hornemann, Mirka Epskamp, Alice Anane, Dana Žáková, Eric Vallabh Minikel, Adriano Aguzzi, Ulrike Camenisch, Raquel Sánchez-Valle, Georg Meisl, Joaquín Castilla, Karl Frontzek, Manfredi Carta, Ewald Lindner, Marco Losa, Jiri G. Safar
Publikováno v:
Neurology
Structured abstractObjectiveTo determine whether naturally occurring autoantibodies against the prion protein are present in individuals with genetic prion disease mutations and controls, and if so, whether they are protective against prion disease.M